前列腺癌患者血清胱抑素C水平与临床评分相关性研究

王雪安; 牛倩; 黄敏; 杨滨; 李贵星; 黄卓春

doi:10.13201/j.issn.1001-1420.2021.03.004

前列腺癌患者血清胱抑素C水平与临床评分相关性研究

- 1. 四川大学华西医院实验医学科(成都, 610041);
- 2. 四川大学华西临床医学院
基金项目:
国家自然科学基金项目(No:81772258)

四川省科技厅科技支撑项目(No:2019YFS0310,2018FZ0106)

详细信息

通讯作者: 黄卓春,E-mail:huangzcscu@163.com

中图分类号: R737.25

收稿日期: 2020-04-21

Correlation between serum Cystatin C level and clinical score in patients with prostate cancer

- 1. Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China;
- 2. West China Medical School, Sichuan University

More Information

Corresponding author: HUANG Zhuochun, E-mail: huangzcscu@163.com

Received Date: 21 April 2020

摘要

摘要: 目的:探讨前列腺癌患者血清胱抑素C(Cystatin C)水平与Gleason评分分数、总前列腺特异性抗原(tPSA)水平及临床分期的相关性。方法:纳入我院前列腺癌患者共142例(前列腺癌组),建立临床资料数据库,对病理切片应用Gleason分级系统对前列腺癌进行组织学分级,使用25.0版本的SPSS软件对数据进行统计学分析,应用t检验对计量资料进行比较。对于不同Gleason评分、不同临床分期、不同tPSA水平的前列腺癌患者与血清Cystatin C水平的相关关系采用Spearman等级相关性检验;对血清Cystatin C含量与年龄的相关性采用Pearson相关分析。以P＜0.05为差异有统计学意义。结果:142例前列腺癌组患者Cystatin C水平高于166例健康对照组,差异有统计学意义[(1.27±0.55) mg/L vs.(0.94±0.18) mg/L,P＜0.001]。在59例有Gleason评分的前列腺癌患者中,血清Cystatin C含量在Gleason评分各组中的差异无统计学意义(P＞0.05)。45例已分期前列腺癌患者中,血清Cystatin C水平与前列腺癌临床分期呈正相关(r=0.386,P＜0.01),Cystatin C含量越高,临床分期越晚。在142例已测tPSA水平前列腺癌患者中,经分析显示,前列腺癌Cystatin C水平与tPSA水平无显著相关性,且差异无统计学意义(r=0.098,P＞0.05)。结论:血清Cystatin C水平对于前列腺癌的早期诊断及临床分期具有重要意义。
- 前列腺癌 /
- 胱抑素C /
- 前列腺特异性抗原 /
- Gleason评分 /
- TNM临床分期
Abstract: Objective: To investigate the relationship between serum Cystatin C level and Gleason score, clinical stage and tPSA level in patients with prostate cancer.Methods: A total of 142 patients with prostate cancer in our hospital were enrolled in this study, and a clinical information database was established. The Gleason grading system was used to analyze the histological grade of prostate cancer. The statistical software SPSS 25.0 was used for statistical analysis. The data were compared by t test. Correlation between serum Cystatin C levels and tPSA levels, different Gleason scores and different clinical stages of prostate cancer were performed using Spearman rank correlation analysis. The correlation between serum Cystatin C content and age was analyzed by Pearson correlation. P＜0.05 suggested that the difference was statistically significant.Results: The level of Cystatin C(1.27±0.55) mg/L in 142 patients with prostate cancer was higher than that in 166 healthy subjects(0.94±0.18) mg/L, and the difference was statistically significant(P＜0.001). There was no significant difference in serum Cystatin C levels among the different Gleason scores in 59 patients with prostate cancer(P＞0.05). In 45 patients with staged prostate cancer, serum Cystatin C level was positively correlated with clinical stage of prostate cancer(r=0.386, P＜0.01). The higher the Cystatin C content, the later the clinical stage. In 142 patients with tPSA level prostate cancer, analysis showed that there was no significant correlation between the level of Cystatin C and tPSA in prostate cancer, and the difference was not statistically significant(r=0.098, P＞0.05).Conclusion: Serum Cystatin C level is of great significance for early diagnosis and clinical staging of prostate cancer.
- prostate cancer /
- Cystatin C /
- prostate specific antigen /
- Gleason score /
- TNM clinical staging

HTML全文

参考文献(19)

[1]	韩苏军.中国前列腺癌发病及死亡现状和流行趋势分析[D].北京:北京协和医学院,2015.
[2]	周刚,彭境罗,刘幸生,等.f/tPSA与PSAD对tPSA灰区且直肠指检阴性前列腺癌诊断价值的Meta分析[J].循证医学,2015,15(1):48-53.
[3]	陶小枫,王晓希,刘维,等.血清IL-6、SAA及PSA检测对前列腺癌的诊断价值[J].山西医科大学学报,2019,50(1):70-74.
[4]	史又文.围手术期快速康复护理对腹腔镜前列腺癌根治术患者免疫功能及炎性反应的影响[J].河北医药,2019,41(18):2877-2880.
[5]	何琳莉,文彬.Cystatin C与恶性肿瘤的关系[J].川北医学院学报,2014,29(3):243-246.
[6]	化宏金,张智弘.基于前列腺癌Gleason评分系统的新分级系统[J].中华病理学杂志,2016,45(7):495-497.
[7]	吴婉莉.Cystatin C与恶性肿瘤进展的关系[J].国外医学老年医学分册,2008,29(2):90-92.
[8]	Luo J,Wang LP,Hu HF,et al.Cystatin C and cardiovascular or all-cause mortality risk in the general population:A meta-analysis[J].Clin Chim Acta,2015,23;450:39-45.
[9]	Xu Y,Ding Y,Li X,et al.Cystatin C is a disease-associated protein subject to multiple regulation[J].Immunol Cell Biol,2015,93(5):442-451.
[10]	Mathews PM,Levy E.Cystatin C in aging and in Alzheimer's disease[J].Ageing Res Rev,2016,32:38-50.
[11]	Chen Q,Fei J,Wu L,et al.Detection of cathepsin B,cathepsin L,cystatin C,urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients[J].Oncol Lett,2011,2(4):693-699.
[12]	王蕾,陈凌燕,刘华.半胱氨酸蛋白酶抑制剂C在胃肠道肿瘤组织中表达的研究[J].中华检验医学杂志,2009,29(12):1133-1136.
[13]	Kolwijck E,Massuger LF,Thomas CM,et al.Cathepsins B,L and cystatin C in cyst fluid of ovarian tumors[J].J Cancer Res Clin Oncol,2010,136(5):771-778.
[14]	Zeng Q,Zhao Y,Yang Y,et al.Expression of cystatin C in human esophageal cancer[J].Tumori,2011,97(2):203-210.
[15]	陈娟娟,张明均,陈中平,等.食管癌患者血清胱抑素C的临床分析[J].检验医学与临床,2016,13(11):1520-1522.
[16]	Kwon WS,Kim TS,Nahm CH,et al.Aberrant cystatin-C expression in blood from patients with breast cancer is a suitable marker for monitoring tumor burden[J].Oncol Lett,2018,16(5):5583-5590.
[17]	Leto G,Crescimanno M,Flandina C.On the role of cystatin C in cancer progression[J].Life Sci,2018,202:152-160.
[18]	Wegiel B,Jiborn T,Abrahamson M,et al.Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways[J].PLoS One,2009,4(11):e7953.
[19]	Zhang J,He P,Zhong Q,et al.Increasing Cystatin C and Cathepsin B in Serum of Colorectal Cancer Patients[J].Clin Lab,2017,63(2):365-371.